dc.contributor.author | Coyle, Caoimhe M. | |
dc.contributor.author | Laws, K.R. | |
dc.date.accessioned | 2015-12-20T16:00:12Z | |
dc.date.available | 2015-12-20T16:00:12Z | |
dc.date.issued | 2015-04-21 | |
dc.identifier.citation | Coyle , C M & Laws , K R 2015 , ' The use of ketamine as an antidepressant: A systematic review and meta-analysis ' , Human Psychopharmacology: Clinical and Experimental , vol. 30 , no. 3 , pp. 152-163 . https://doi.org/10.1002/hup.2475 | |
dc.identifier.issn | 0885-6222 | |
dc.identifier.other | ORCID: /0000-0002-5065-0867/work/124446514 | |
dc.identifier.uri | http://hdl.handle.net/2299/16556 | |
dc.description | This is the peer reviewed version of the following article: Caoimhe M. Coyle, and Keith R. Laws, ‘The use of ketamine as an antidepressant: a systematic review and meta-analysis’, Human Psychopharmacology, Vol. 30 (3): 152-163, May 2015, which has been published in final form at https://doi.org/10.1002/hup.2475. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. | |
dc.description.abstract | Objective The current meta-analysis examines the effects of ketamine infusion on depressive symptoms over time in major depressive disorder (MDD) and bipolar disorder (BD). Methods Following a systematic review of the literature, data were extracted from 21 studies (n = 437 receiving ketamine) and analysed at four post-infusion time points (4 h, 24 h, 7 days and 12-14 days). The moderating effects of several factors were assessed including: repeat/single infusion, diagnosis, open-label/participant-blind infusion, pre-post/placebo-controlled design and the sex of patients. Results Effect sizes were significantly larger for repeat than single infusion at 4 h, 24 h and 7 days. For single infusion studies, effect sizes were large and significant at 4 h, 24 h and 7 days. The percentage of males was a predictor of antidepressant response at 7 days. Effect sizes for open-label and participant-blind infusions were not significantly different at any time point. Conclusions Single ketamine infusions elicit a significant antidepressant effect from 4 h to 7 days; the small number of studies at 12-14 days post infusion failed to reach significance. Results suggest a discrepancy in peak response time depending upon primary diagnosis - 24 h for MDD and 7 days for BD. The majority of published studies have used pre-post comparison; further placebo-controlled studies would help to clarify the effect of ketamine over time. | en |
dc.format.extent | 12 | |
dc.format.extent | 846038 | |
dc.language.iso | eng | |
dc.relation.ispartof | Human Psychopharmacology: Clinical and Experimental | |
dc.subject | bipolar disorder | |
dc.subject | depression | |
dc.subject | ketamine | |
dc.subject | major depressive disorder | |
dc.subject | Clinical Neurology | |
dc.subject | Psychiatry and Mental health | |
dc.subject | Neurology | |
dc.subject | Pharmacology (medical) | |
dc.title | The use of ketamine as an antidepressant: : A systematic review and meta-analysis | en |
dc.contributor.institution | Health & Human Sciences Research Institute | |
dc.contributor.institution | School of Life and Medical Sciences | |
dc.contributor.institution | Department of Psychology | |
dc.contributor.institution | Psychology | |
dc.contributor.institution | Cognitive Neuropsychology | |
dc.description.status | Peer reviewed | |
rioxxterms.versionofrecord | 10.1002/hup.2475 | |
rioxxterms.type | Journal Article/Review | |
herts.preservation.rarelyaccessed | true | |